NGS Automation Market (2026-2036)
The global NGS Automation Market was valued at USD 752.4 million in 2025. This market is expected to reach USD 2,853.3 million by 2036 from an estimated USD 855.1 million in 2026, registering a CAGR of 12.8% during the forecast period (2026-2036).
- Published
- Sep 2026
- Pages
- 212
- Format
- PDF + Excel
- Report ID
- MRHC - 104585
- Base year
- 2025
- 2025 · BASELINE
- $752.4M
- 2036
- $2.85B
- CAGR 2026–2036
- 12.8%
2025 baseline · 2026–2036 forecast at 12.8% CAGR · hover a bar for the value
Key highlights
The global NGS Automation Market was valued at USD 752.4 million in 2025.
This market is expected to reach USD 2, 853.3 million by 2036 from an estimated USD 855.1 million in 2026, registering a CAGR of 12.8% during the forecast period (2026-2036).
In 2026, North America is expected to account for the largest share of 44.0% of the global NGS Automation Market.
Europe is expected to account for the second-largest share of 27.8% of the NGS automation market in 2026. The significant share of Europe is attributed to national genomic medicine programs in the U.K., Germany, and France, a large pharmaceutical and research base, and the presence of major sequencing service providers.
However, Asia-Pacific is projected to register the highest CAGR of 15.5% during the forecast period. The growth of this region is driven by the scale of sequencing providers in China, domestic automation and sequencing platforms from MGI Tech, national genome programs in India, South Korea, Singapore, and Japan, and rising clinical and pharmaceutical sequencing.
Latin America is expected to account for a share of 4.8% of the NGS automation market in 2026. The market in the region is driven by the growing use of sequencing in oncology and prenatal screening, pharmaceutical clinical trial activity, and national genomics initiatives, while large private diagnostic groups in Brazil and Mexico are adding in-house sequencing capacity.
The Middle East & Africa is expected to account for a share of 2.6% of the NGS automation market in 2026. The market is driven by national genome programs in the Gulf states, high rates of consanguinity that increase the prevalence of recessive genetic disorders, and investment in genomic medicine infrastructure.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026-2036 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR (Value) | 12.8% |
| Format | PDF, Excel & Cloud Portal · 212 pages |
| Market Size (Value) in 2026 | USD 855.1 Million |
| Market Size (Value) in 2036 | USD 2,853.3 Million |
| Segments Covered | By Product: Workstations/Robotic Platforms, Reagents & Consumables. By Sequencing Type: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing, Other Sequencing Types. By Application: Research & Other Applications (Drug Discovery, Agriculture & Animal Research, Other Research Applications), Clinical Applications (Oncology, Reproductive Health, Infectious Diseases, Other Clinical Applications). By End User: Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Academic Institutes & Research Centers, Other End Users. |
| Countries Covered | North America: U.S., Canada. Europe: Germany, France, U.K., Italy, Spain, Rest of Europe. Asia-Pacific: China, Japan, India, Rest of Asia-Pacific. Latin America: Brazil, Mexico, Rest of Latin America. Middle East & Africa. |
| Key Companies | Danaher Corporation, Tecan Group Ltd., Revvity, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Hamilton Company, Eppendorf SE, SPT Labtech, Opentrons Labworks, Inc., MGI Tech Co., Ltd., and F. Hoffmann-La Roche Ltd. |
Report overview
Segments covered: product, sequencing type, application, clinical application, end user.
The growth of this market is mainly driven by the growing demand for optimized and streamlined NGS workflows, rising sequencing volumes as the cost per genome falls, persistent laboratory workforce shortages, the expansion of accredited clinical sequencing, and large population and newborn sequencing programs. In addition, the launch of lower-cost benchtop and application-specific systems, partnerships between sequencing, reagent, and automation companies to develop validated automated methods, and the integration of artificial intelligence into laboratory automation software are further supporting the growth of this market.
The global NGS Automation Market is projected to reach USD 2,853.3 million by 2036, driven by rising sequencing volumes, persistent laboratory workforce shortages, the expansion of accredited clinical sequencing, and large population and newborn sequencing programs.
North America is expected to account for the largest market share of 44.0% in 2026, while Asia-Pacific is projected to register the fastest growth at a CAGR of 15.5% during the forecast period, and India is projected to register the highest CAGR of any country, at 17.6%.
By product, Workstations/Robotic Platforms are expected to account for the larger market share of 73.5% in 2026 and to register the higher CAGR of 12.9% through 2036.
By sequencing type, Whole Genome Sequencing is expected to account for the largest share of 40.3% in 2026 and to register the highest CAGR of 13.6%, driven by population, newborn, and clinical genome sequencing.
Automation cuts the operator time for library preparation by about 80%. A 2024 study at Leiden University Medical Center found that automating Illumina DNA Prep on a liquid handler reduced hands-on time for eight libraries from 125 minutes to 25 minutes, with results 100% concordant with the manual workflow.
The entry price for NGS automation has fallen sharply. The Opentrons Flex High-Throughput NGS Workstation, launched in January 2025, runs library preparation hands-free for up to 96 samples at less than USD 100,000, against about USD 124,000 to USD 225,000 for traditional open workstations.
The market is concentrated. Danaher Corporation through Beckman Coulter Life Sciences, Tecan Group, Revvity, Agilent Technologies, and Thermo Fisher Scientific together held an assessed 83.2% of the NGS workstations segment in 2025.
The NGS Automation Market comprises the automated liquid handling workstations, robotic platforms, dedicated library preparation systems, and associated reagents and consumables used to automate sample and library preparation for next-generation sequencing. Library preparation is the step of the NGS workflow that has changed least as sequencing has scaled. A production-scale sequencer can now generate a human genome for about USD 200, but every sample must still pass through extraction, quantification, fragmentation, end repair, adapter ligation, amplification, several bead clean-ups, normalization, and pooling before it is sequenced. Manual preparation of a batch of libraries typically takes two to three days, while automated liquid handling reduces the hands-on part of this work to one to two hours, according to Eppendorf, and dedicated walkaway systems reduce it to minutes.
The market is served by three groups of suppliers. Open liquid handling platforms, such as the Beckman Coulter Biomek, Hamilton Microlab STAR, Tecan Fluent, and Revvity Sciclone and JANUS systems, run a wide range of validated methods. Dedicated library preparation systems, such as the Agilent Magnis, Roche AVENIO Edge, Beckman Coulter Biomek NGeniuS, and SPT Labtech firefly, are designed for walkaway operation with matched reagents. Entry-level robots, such as the Opentrons Flex, have brought automation within reach of smaller laboratories.
The cost of sequencing has fallen far faster than the cost of preparing samples. According to the National Human Genome Research Institute, the cost per genome fell from about USD 29,092 in 2010 to USD 562 in 2021, and production-scale genomes on the NovaSeq X Plus now cost about USD 200. As a result, the share of total workflow cost and time taken by sample preparation has risen, making automation the main lever for scaling sequencing throughput.
Clinical sequencing volumes are rising rapidly. Natera reported about 800,800 oncology tests in 2025, up from about 528,200 in 2024, Guardant Health reported about 276,000 oncology tests, up 34%, and GeneDx reported 97,271 exome and genome tests, up 30.5%. National programs sequence samples at volumes that are only feasible with high-throughput automation: UK Biobank completed whole genome sequencing of its 500,000 participants, the Emirati Genome Programme has sequenced more than 800,000 genomes, and the National Project of Bio-Big Data of Korea targets whole genome sequencing for 550,000 individuals.
The market recovered from a weak period for life science instruments in 2025. Tecan reported 2025 sales of CHF 882.5 million, down 1.6% in local currencies, but order entry grew 8.6% in the second half of 2025 and sales grew 3.4% in the first half of 2026, with diagnostic customers the most resilient. At the same time, suppliers launched lower-cost systems that extend automation to smaller laboratories, including the Opentrons Flex High-Throughput NGS Workstation in January 2025, the Beckman Coulter Biomek i3 in December 2025, and the Illumina and SPT Labtech fireflyGO in May 2026.
Expansion of Accredited Clinical Sequencing and Large Population Sequencing Programs
Clinical laboratories accredited under CAP and ISO 15189 require reproducible, documented processes, which favors automated library preparation. The largest clinical laboratories are adding hundreds of thousands of tests a year, with Natera reporting about 800,800 oncology tests in 2025. At the same time, national genome programs, such as UK Biobank, the Emirati Genome Programme, and the National Project of Bio-Big Data of Korea, and newborn sequencing programs, including the U.K. Generation Study, which had recruited 52,000 newborns by March 2026, each generate hundreds of thousands of libraries over a few years, driving demand for high-throughput automation.
NGS Automation Market Restraints
High Costs of Automation Workstations
Automation requires capital investment before any sample is processed. Open NGS workstations from leading suppliers have typically been priced between about USD 50,000 and USD 250,000, depending on configuration, with list prices ranging from about USD 124,000 for the Hamilton Microlab STAR to about USD 225,000 for the Revvity Sciclone NGSx iQ Workstation. Automated methods must also be validated before routine use, service contracts add a recurring annual cost, and automated workflows use more plastic consumables per sample than manual methods. The total cost of ownership is therefore considerably higher than the instrument price.
Constrained Research Budgets
Instrument purchases by academic and government laboratories fell in 2025. Tecan reported that its Life Sciences Business sales declined to CHF 377.1 million from CHF 397.0 million, as demand for instruments in academia and government was significantly affected by budget uncertainty and volatile public funding, particularly in the U.S. and China. Public research funding has become the most volatile source of demand for automation.
NGS Automation Market Opportunities
Lower-Cost Benchtop and Application-Specific Systems
Suppliers are extending automation to laboratories that could not previously justify it. The Opentrons Flex robot is sold at USD 22,250 to USD 51,250 depending on configuration, and the Opentrons Flex High-Throughput NGS Workstation runs library preparation hands-free for up to 96 samples at less than USD 100,000. The Beckman Coulter Biomek i3, launched in December 2025, and the Illumina and SPT Labtech fireflyGO, launched in May 2026, further expand the range of compact, application-specific systems available to smaller clinical and research laboratories.
Partnerships to Develop Validated Automated Methods
The value of an automation platform depends on the library preparation methods it can run. A laboratory that buys a workstation expects to run the kits it already uses, and each method that has not been validated by the supplier must be developed and tested in-house. Sequencing companies now treat automation as part of the product: Ultima Genomics partnered with Hamilton in February 2026 to automate sample preparation and amplification for its systems, and MGI Tech sells its own MGISP automated sample preparation systems alongside its DNBSEQ sequencers. Partnerships that expand the breadth of validated methods create significant growth opportunities for automation suppliers.
Integration of Artificial Intelligence and Software
Software is becoming a differentiator in laboratory automation. Tecan announced agentic AI developments for laboratory automation powered by NVIDIA in June 2026, Agilent entered a collaboration with OpenAI and Boston Consulting Group in June 2026 to deploy AI across its products and customer workflows, and Opentrons has built AI-assisted protocol generation around a library of more than 100 validated Flex protocols. AI is expected to lower the skill required to design and run automated methods, expanding the addressable base of laboratories.
NGS Automation Market Challenges
Validation Requirements for Clinical Automation
Clinical laboratories must validate each automated method before using it for patient testing, including accuracy, precision, carry-over contamination, and comparison with the manual method. CAP accreditation checklists and ISO 15189 require documented validation of each test system, and any change to the platform, software, or reagents may require revalidation. Validation also creates lock-in, which slows the adoption of newer, cheaper, or faster systems in clinical settings.
Need for Trained Personnel and Limited Interoperability
Open liquid handling platforms offer flexibility but require programming and troubleshooting skills that many laboratories lack, and many laboratories under-use the automation they own. Library preparation kits, sequencers, and automation platforms also come from different suppliers, and a method validated on one liquid handler must be adapted to run on another. With Roche, Element Biosciences, and Ultima Genomics launching new sequencing systems in 2026, each with its own library preparation requirements, the number of combinations that must be validated keeps rising.
NGS Automation Market Trends
Shift Toward Walkaway, Sample-to-Library Systems
Laboratories increasingly prefer systems that take a sample and return a sequencing-ready library with minimal intervention. These systems combine liquid handling with on-board thermal cycling, magnetic separation, and quantification, and come with pre-aliquoted reagents and locked protocols, which reduces hands-on time and simplifies validation in clinical settings.
Localization of Supply in China
Supply in China is shifting toward domestic platforms. China placed Illumina on its Unreliable Entities List in February 2025, and MGI Tech sold more than 1,470 sequencers in 2025, including 898 to clinical customers, up 67.54%. MGI reported that its intelligent automation business sold more than 350 units in 2025, generating revenue of RMB 254 million. Laboratories moving to domestic sequencers tend to adopt the automation validated for those platforms.
Automation of Single-Cell, Long-Read, and RNA Workflows
Automation is extending beyond short-read DNA library preparation. The Opentrons Flex High-Throughput NGS Workstation supports whole genome, long-read, and single-cell library preparation, Hamilton and Takara Bio USA are automating SMART-Seq full-length RNA library preparation, and HP expanded its collaboration with Tecan in May 2025 with a digital dispenser for single-cell and low-volume applications.
NGS Automation Market Segment Analysis
NGS Automation Market Analysis by Product
Based on product, the global NGS Automation Market is segmented into Workstations/Robotic Platforms and Reagents & Consumables. In 2026, the Workstations/Robotic Platforms segment is expected to account for the larger share of 73.5% of the global NGS Automation Market. The large share of this segment is mainly due to the high unit value of automation instruments and to replacement and first-time purchases. This segment is also projected to register the higher CAGR of 12.9% during the forecast period, supported by the launch of lower-cost benchtop and application-specific systems, while Reagents & Consumables grow with the installed base.
NGS Automation Market Analysis by Sequencing Type
Based on sequencing type, the market is segmented into Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing, and Other Sequencing Types. In 2026, the Whole Genome Sequencing segment is expected to account for the largest share of 40.3% of the NGS automation market. This segment is also projected to register the highest CAGR of 13.6% during the forecast period, driven by population, newborn, and clinical genome sequencing programs that generate hundreds of thousands of libraries.
NGS Automation Market Analysis by Application
Based on application, the market is segmented into Research & Other Applications (Drug Discovery, Agriculture & Animal Research, and Other Research Applications) and Clinical Applications (Oncology, Reproductive Health, Infectious Diseases, and Other Clinical Applications). In 2026, the Research & Other Applications segment is expected to account for the larger share of 65.5% of the NGS automation market. However, the Clinical Applications segment is projected to register the higher CAGR of 13.9%, and within it Oncology is projected to register the highest CAGR of 15.1%, driven by rising volumes of tumor profiling and liquid biopsy testing.
NGS Automation Market Analysis by End User
Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Academic Institutes & Research Centers, and Other End Users. In 2026, the Pharmaceutical & Biotechnology Companies segment is expected to account for the largest share of 54.5% of the NGS automation market. However, the Hospitals & Diagnostic Laboratories segment is projected to register the highest CAGR of 13.8% during the forecast period, driven by clinical sequencing growth, accreditation requirements, and workforce shortages.
NGS Automation Market Competitive Landscape
The global NGS Automation Market is concentrated, with competition among suppliers of open liquid handling platforms, dedicated library preparation systems, entry-level robots, and sequencing platform companies that offer their own automation. Market participants compete primarily on the breadth of validated library preparation methods, walkaway capability, throughput, reliability, software ease of use, service and application support, and total cost of ownership.
The five largest participants, Danaher Corporation through Beckman Coulter Life Sciences, Tecan Group, Revvity, Agilent Technologies, and Thermo Fisher Scientific, together held an assessed 83.2% of the NGS workstations segment in 2025, with Danaher holding the leading assessed share of 32.6%. Product launches and partnerships with reagent and sequencing companies to develop validated automated methods were the most common growth strategies in 2025 and 2026, including the fireflyGO launch by Illumina and SPT Labtech in May 2026 and the partnership between Ultima Genomics and Hamilton in February 2026.
The report provides a comprehensive competitive assessment of the leading companies operating in the global NGS Automation Market. The key players profiled in the report include Danaher Corporation (U.S.), Tecan Group Ltd. (Switzerland), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Hamilton Company (U.S.), Eppendorf SE (Germany), SPT Labtech (U.K.), Opentrons Labworks, Inc. (U.S.), MGI Tech Co., Ltd. (China), and F. Hoffmann-La Roche Ltd (Switzerland).
Market dynamics
2 factors across 1 forceGrowing Demand for Optimized and Streamlined NGS Workflows
Manual library preparation is slow, repetitive, and error-prone. Each step requires precise pipetting of small volumes in a fixed order, and a single error can waste a sample that is often available only once, such as a tumor biopsy or a newborn blood spot. Published comparisons show the scale of the gain from automation. A 2024 study at Leiden University Medical Center, published in Scientific Reports, found that automating Illumina DNA Prep on a liquid handler reduced hands-on time for eight libraries from 125 minutes to 25 minutes, turnaround time fell from 200 to 170 minutes, and results were 100% concordant with the manual workflow. Laboratories are therefore reducing the number of manual touchpoints in the workflow through automation.
Rising Sequencing Volumes and Persistent Laboratory Workforce Shortages
Falling sequencing costs are increasing the number of samples each laboratory processes, while the availability of trained staff has not kept pace. The 2024 Vacancy Survey of the American Society for Clinical Pathology (ASCP), based on 1,027 responses covering 18,626 laboratory employees in the U.S., found that vacancy rates remained above pre-pandemic levels, and the U.S. records about 22,600 openings a year for clinical laboratory technologists and technicians. Automation allows laboratories to process more samples with the staff they have, which makes it a direct response to both rising volumes and workforce constraints.
Table of contents
12 chapters · 184 sections · 212 pages · click to expandGeographic analysis
North America
Largest shareIn 2026, North America is expected to account for the largest share of 44.0% of the global NGS Automation Market. The large share of North America is attributed to the concentration of clinical sequencing laboratories, sequencing service providers, and pharmaceutical companies in the region, the large installed base of automation, and persistent laboratory workforce shortages. Most of the leading automation suppliers are based in the U.S., including Beckman Coulter Life Sciences, Hamilton Company, Agilent Technologies, Thermo Fisher Scientific, Revvity, and Opentrons. Natera, Guardant Health, and GeneDx reported revenue growth of 30% or more in 2025, while academic sequencing was held back by the proposed cut of nearly 40% to the National Institutes of Health budget for fiscal 2026.
Europe
Europe is expected to account for the second-largest share of 27.8% of the NGS automation market in 2026. The significant share of Europe is attributed to national genomic medicine programs in the U.K., Germany, and France, a large pharmaceutical and research base, and the presence of major sequencing service providers. Europe is also home to leading automation suppliers, including Tecan and Roche in Switzerland, Eppendorf in Germany, and SPT Labtech in the U.K. The German model project for genome sequencing, the French Genomic Medicine Plan, and the NHS Genomic Medicine Service route funded clinical sequencing to designated high-throughput centers. Germany is expected to account for the largest share of the regional market in 2026.
Asia-Pacific
Fastest growthHowever, Asia-Pacific is projected to register the highest CAGR of 15.5% during the forecast period. The growth of this region is driven by the scale of sequencing providers in China, domestic automation and sequencing platforms from MGI Tech, national genome programs in India, South Korea, Singapore, and Japan, and rising clinical and pharmaceutical sequencing. China is expected to account for the largest share of the regional market in 2026, while India is projected to register the highest CAGR of any country, at 17.6%. The GenomeIndia project sequenced 10,000 genomes from 99 population groups, and suppliers are expanding their presence, with Tecan establishing direct sales and specialist service operations in India in May 2026 and Agilent opening its India Solution Center in May 2025.
Latin America
Latin America is expected to account for a share of 4.8% of the NGS automation market in 2026. The market in the region is driven by the growing use of sequencing in oncology and prenatal screening, pharmaceutical clinical trial activity, and national genomics initiatives, while large private diagnostic groups in Brazil and Mexico are adding in-house sequencing capacity. Limited public reimbursement remains the main constraint, and Brazil is expected to account for the largest share of the regional market in 2026.
Middle East & Africa
The Middle East & Africa is expected to account for a share of 2.6% of the NGS automation market in 2026. The market is driven by national genome programs in the Gulf states, high rates of consanguinity that increase the prevalence of recessive genetic disorders, and investment in genomic medicine infrastructure. The UAE has sequenced more than 800,000 genomes under the Emirati Genome Programme since its launch in 2019, and Saudi Arabia and Qatar run national genome programs linked to premarital and newborn screening.
Competitive landscape
- Danaher Corporation
- Tecan Group Ltd.
- Revvity, Inc.
- Agilent Technologies, Inc.
- Thermo Fisher Scientific Inc.
- Hamilton Company
- Eppendorf SE
- SPT Labtech
- Opentrons Labworks, Inc.
- MGI Tech Co., Ltd.
- F. Hoffmann-La Roche Ltd
Expert perspectives
The NGS Automation Market is moving from its origins in large genome centers and pharmaceutical research toward clinical laboratories and smaller research sites. As sequencing costs have fallen to about USD 200 per genome, sample and library preparation has become the main bottleneck in the NGS workflow, and automation now determines how many samples a laboratory can process with the staff it has and how consistent those samples are.
Three structural changes are expected to shape competitive positions through 2036. First, lower-cost benchtop and application-specific systems are opening the market to laboratories that could not previously justify automation, which increases unit volumes but pressures average selling prices. Second, sequencing platform companies are treating automation as part of the product, which favors automation suppliers with partnerships and validated methods on multiple sequencing platforms. Third, software and artificial intelligence are becoming differentiators, as suppliers compete to reduce the skill required to design, validate, and run automated methods.
For companies planning entry or expansion, the most defensible positions over the forecast period are likely to be found in walkaway sample-to-library systems for clinical laboratories, validated methods for whole genome and single-cell workflows, and application support in Asia-Pacific, particularly in India. For established suppliers, the principal risk is the volatility of academic and government demand and the shift of Chinese demand toward domestic platforms.
Frequently asked questions
The global NGS Automation Market is estimated at USD 855.1 million in 2026.
Cite this report
Meticulous Research. (2026). NGS Automation Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MRHC - 104585). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/ngs-automation-market-5271